Adriamycin pfs and Gastrointestinal inflammation - a phase IV clinical study of FDA data

Summary:

Gastrointestinal inflammation is reported only by a few people who take Adriamycin Pfs.

The phase IV clinical study analyzes which people take Adriamycin pfs and have Gastrointestinal inflammation. It is created by eHealthMe based on reports of 6,484 people who have side effects while taking Adriamycin pfs from the FDA, and is updated regularly.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.

On Jun, 30, 2022

6,484 people reported to have side effects when taking Adriamycin pfs.
Among them, 3 people (0.05%) have Gastrointestinal inflammation.

What is Adriamycin pfs?

Adriamycin pfs has active ingredients of doxorubicin hydrochloride. eHealthMe is studying from 6,495 Adriamycin pfs users for its effectiveness, alternative drugs and more.

What is Gastrointestinal inflammation?

Gastrointestinal inflammation (inflammation of stomach and intestine) is found to be associated with 759 drugs and 492 conditions by eHealthMe.

Number of Adriamycin pfs and Gastrointestinal inflammation reports submitted per year:

Could Adriamycin pfs cause Gastrointestinal inflammation?

Time on Adriamycin pfs when people have Gastrointestinal inflammation *:

Gender of people who have Gastrointestinal inflammation when taking Adriamycin pfs *:

female: 100 %
male: 0.0 %

Age of people who have Gastrointestinal inflammation when taking Adriamycin pfs *:

Common drugs people take besides Adriamycin pfs *:

Common side effects people have besides Gastrointestinal inflammation *:

Abdominal Pain: 3 people, 100.00%
Urine Output Decreased: 2 people, 66.67%
Reversible Posterior Leukoencephalopathy Syndrome (a brain disease with generalized seizures and headache): 2 people, 66.67%
Blood Amylase Increased: 2 people, 66.67%
Nausea And Vomiting: 1 person, 33.33%
Nausea (feeling of having an urge to vomit): 1 person, 33.33%
Gastrointestinal Infection (infection of stomach and intestine): 1 person, 33.33%
Fever: 1 person, 33.33%
Diarrhea: 1 person, 33.33%
Blood Culture Positive: 1 person, 33.33%

Common conditions people have *:

Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 66.67%
Lymphoma (cancer that begins in immune system cells): 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Adriamycin pfs and have Gastrointestinal inflammation?

Check whether Gastrointestinal inflammation is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, "Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn9s disease", Gut, 2016 Mar .

Related studies

Alternative drugs to, pros and cons of Adriamycin pfs:

Adriamycin pfs (6,495 reports)

Gastrointestinal inflammation treatments and more:

Gastrointestinal inflammation (6,885 reports)

COVID vaccines that are related to Gastrointestinal inflammation:

How severe was Gastrointestinal inflammation and when was it recovered:

Gastrointestinal inflammation in Adriamycin pfs

Expand to all the drugs that have ingredients of doxorubicin hydrochloride:

Gastrointestinal inflammation and drugs with ingredients of doxorubicin hydrochloride

Common drugs associated with Gastrointestinal inflammation:

How the study uses the data?

The study uses data from the FDA. It is based on doxorubicin hydrochloride (the active ingredients of Adriamycin pfs) and Adriamycin pfs (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.